Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATORGO
2023-504654-35-00Phase 2Authorised
- Sponsor
- Region Skåne
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atorvastatin in Graves Orbitopathy (GO), sponsored by Region Skåne. Primary endpoint: Proportion of patients developing active Graves ophthalmopathy at 12 months. Planned start Feb 2026; status: authorised.
02
Drugs
atorvastatin
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-504654-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504654-35-00.